Related Experiment Video
Updated: Jun 23, 2026
08:05
Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
[Notes to the regulatory Appendix 13 of the Italian Committee for Drugs]
Summary
Italian guidelines for hypolipidemic agents are confusing and use inappropriate risk charts. Using Framingham-derived risk functions for Italy is inaccurate for cardiovascular disease prevention.
Area of Science:
- Cardiovascular Disease Prevention
- Pharmacoeconomics
- Medical Guidelines
Context:
- Recent modifications to Italian regulations concerning hypolipidemic agents for heart disease prevention.
- Widespread use of risk assessment tools, including Framingham-based charts, in European and Italian guidelines.
- Growing interest in coronary risk estimation driven by statin trials and preventative cardiology research.
Purpose:
- To comment on the conceptual, terminological, and definitional ambiguities in the updated "Appendix 13".
- To critique the inappropriateness of using Framingham-derived risk charts for the Italian population.
- To clarify the categorization of high-risk individuals within the current regulatory framework.
Summary:
- The Italian Committee for Drugs' "Appendix 13" presents unclear guidelines for hypolipidemic agent reimbursement.
- It incorrectly suggests using Framingham risk charts, which are unsuitable for estimating absolute coronary risk in Italy due to population differences.
- The document lacks clarity on defining disease and categorizing high-risk patients, necessitating a re-evaluation of risk assessment tools.
Impact:
- Highlights the inadequacy of applying foreign risk prediction models to diverse populations, potentially leading to misinformed clinical decisions.
- Underscores the need for region-specific risk assessment tools in cardiovascular disease prevention strategies.
- Emphasizes the importance of clear, accurate, and contextually relevant guidelines for drug reimbursement and patient management.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:15Drug Dosage Regimen: Overview
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...